🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

514 results for “Vir” Clear

  1. Molnupiravir

    Merck KGaA, Darmstadt, Germany

    Coronavirus Disease (COVID-19)

    phase 3 small molecule active

    2 trials

  2. Molnupiravir Matching placebo tablets, molnupiravir

    Merck Sharp and Dohme

    SARS-CoV-2 (COVID-19) infection

    phase 3 small molecule active

    1 trial

  3. NIRMATRELVIR, NIRMATRELVIR, Ritonavir, nirmatrelvir / ritonavir

    Pfizer Australia Pty Ltd

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  4. PEG-Interferon a-2b + Ribavirin

    Universal Integrated

    Chronic Hepatitis C Infection in HIV-Infected Persons

    phase 3 small molecule completed

    1 trial

  5. PREVYMIS 240 mg film-coated tablets, Placebo of prevymis 240 mg tablets (letermovir), VALGANCICLOVIR

    Pari Pharma GmbH

    CytoMegaloVirus infections, Kidney transplant

    phase 3 small molecule active

    1 trial

  6. PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead Sciences Pty Limited

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  7. Peramivir

    Biocryst

    Seasonal Influenza

    phase 3 small molecule completed

    1 trial

  8. Peramivir

    Biocryst

    Influenza

    phase 3 small molecule completed

    5 trials

  9. Peramivir 150mg

    Biocryst

    Influenza

    phase 3 small molecule terminated

    1 trial

  10. Peramivir+SOC

    Biocryst

    Cough

    phase 3 small molecule terminated

    1 trial

  11. Pimodivir 600 mg

    Janssen Cilag International NV

    Influenza A

    phase 3 small molecule terminated

    1 trial

  12. Placebo

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial

  13. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  14. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  15. Placebo is 0.9% (w/v) NaCl for injection and is to be provided by sites., IVX-A12

    AstraZeneca AB

    Respiratory Syncytial Virus and Human Metapneumovirus

    phase 3 small molecule active

    1 trial

  16. Placebo is a solution for infusion of human albumin 1%, is an albumin preparation manufactured by dilution from the drug product of Albiomin 20%, it will be administrated via intravenous infusion., Trimodulin (human IgM, IgA, IgG solution)

    Biotest Pharma GmbH

    Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule active

    1 trial

  17. Placebo to Ibuzatrelvir film-coated tablet, PF-07817883 Tablet

    Pfizer Australia Pty Ltd

    Covid-19 at high risk of progression to severe illness.

    phase 3 small molecule active

    1 trial

  18. Placebo to Remdesivir - Saline, Remdesivir, PF-07817883 Tablet, Placebo to Ibuzatrelvir

    Pfizer Australia Pty Ltd

    Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule active

    1 trial

  19. Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  20. RESPIRATORY SYNCYTIAL VIRUS VACCINES

    The George Institute

    RSV infection

    phase 3 small molecule active

    1 trial

  21. RSV MAT

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 mab terminated

    1 trial

  22. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)

    The George Institute

    Rabies infection/prophylaxis

    phase 3 small molecule active

    1 trial

  23. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in Fertigspritze Tollwutvirus (inaktiviert, Stamm Flury LEP)

    The George Institute

    Rabies

    phase 3 small molecule active

    1 trial

  24. Raltegravir

    United Therapeutics Europe Ltd

    Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources